Abstract |
A pilot dose-escalation study of recombinant human interleukin 12 (rhIL-12) was conducted in Japanese patients with advanced malignancies. Cohorts of three patients received escalating doses of rhIL-12 that increased from 50 to 300 ng/kg/day s.c. three times a week for 2 weeks followed by 1-week rest. The same dosage and schedule was repeated for two additional courses. Sixteen previously treated patients were registered, and 15 were evaluated. Common toxicities were fever and leukopenia; the abnormality of laboratory tests included elevations in aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, C-reactive protein, and beta2-microglobin. Dose-limiting toxicity was the grade 3 elevation of aminotransferases, and was observed in two of six patients at the 300-ng/kg dose level after the first course in one patient and after the third course in the other. Leukopenia was observed at all of the dose levels; two of six patients at 300 ng/kg experienced grade 3 leukopenia. Thus, 300 ng/kg was determined to be the maximum acceptable dose. Peak plasma levels of rhIL-12 decreased in the second courses, but the areas under the curve were almost the same in the first and second courses. Biological effects included increases of plasma levels of IFN-gamma, tumor necrosis factor-alpha, IL-6, IL-10, and neopterin. In two patients with renal cell carcinoma, complete response and partial response of metastatic tumors were observed with 50 and 300 ng/kg; the responses lasted for 5 and 3.5 months, respectively. Although immunological response to rhIL-12 varies depending on administration route and schedule and on patients' physiological conditions, the recommended dose for Phase II studies is 300 ng/kg s.c. three times a week for 2 weeks followed by 1-week rest.
|
Authors | R Ohno, Y Yamaguchi, T Toge, T Kinouchi, T Kotake, M Shibata, Y Kiyohara, S Ikeda, I Fukui, A Gohchi, Y Sugiyama, S Saji, S Hazama, M Oka, K Ohnishi, Y Ohhashi, S Tsukagoshi, T Taguchi |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 6
Issue 7
Pg. 2661-9
(Jul 2000)
ISSN: 1078-0432 [Print] United States |
PMID | 10914707
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Multicenter Study)
|
Chemical References |
- Interleukin-6
- Recombinant Proteins
- Tumor Necrosis Factor-alpha
- Interleukin-10
- Neopterin
- Interferon-gamma
|
Topics |
- Adult
- Aged
- Carcinoma, Renal Cell
(drug therapy)
- Cohort Studies
- Dose-Response Relationship, Drug
- Female
- Humans
- Infusions, Intravenous
- Interferon-gamma
(blood)
- Interleukin-10
(administration & dosage, adverse effects, blood, pharmacokinetics)
- Interleukin-6
(blood)
- Japan
- Kidney Neoplasms
(drug therapy)
- Male
- Middle Aged
- Neoplasms
(blood, drug therapy, immunology)
- Neopterin
(blood)
- Recombinant Proteins
(administration & dosage, adverse effects, pharmacokinetics)
- Tumor Necrosis Factor-alpha
(analysis)
|